|
|
Article: SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing.
- Article from:
- Biotech Week
- Article date:
- May 13, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma. SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride (see also Hair Loss).
Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair. However, due to potential ...